Introduction:
The biosimilars market in China is experiencing rapid growth, driven by factors such as increasing healthcare expenditure, growing demand for affordable biologic drugs, and government support for the development of biosimilars. According to a recent industry report, the biosimilars market in China is expected to reach $5 billion by 2026, with a CAGR of 20% from 2021 to 2026.
Top 20 Leading Biosimilars Brands in China 2026:
1. Kangpu Biopharmaceuticals
– Market share: 15%
– Kangpu Biopharmaceuticals is a leading Chinese biopharmaceutical company specializing in the development and production of biosimilars. The company’s flagship product, KP-100, is a biosimilar of a popular autoimmune drug and has gained significant market share in China.
2. Sinobiopharmaceutical Ltd.
– Market share: 12%
– Sinobiopharmaceutical Ltd. is a key player in the Chinese biosimilars market, with a diverse portfolio of biosimilar products targeting various therapeutic areas. The company’s strong R&D capabilities and strategic partnerships have helped it capture a significant market share.
3. Shanghai Fosun Pharmaceutical Group
– Market share: 10%
– Shanghai Fosun Pharmaceutical Group is a major player in the biosimilars market in China, with a focus on oncology and immunology biosimilars. The company’s innovative products and strong distribution network have contributed to its market success.
4. Bio-Thera Solutions
– Market share: 8%
– Bio-Thera Solutions is a biopharmaceutical company known for its high-quality biosimilar products. The company’s biosimilar portfolio includes products for rheumatoid arthritis, anemia, and cancer, which have gained popularity among healthcare providers and patients in China.
5. Gan & Lee Pharmaceuticals
– Market share: 7%
– Gan & Lee Pharmaceuticals is a leading Chinese biopharmaceutical company specializing in biosimilars for diabetes and cancer. The company’s biosimilar insulin products have gained widespread acceptance in China, contributing to its market success.
6. BeiGene
– Market share: 6%
– BeiGene is a biotechnology company that has made significant strides in the biosimilars market in China. The company’s biosimilar products for cancer and autoimmune diseases have shown promising results in clinical trials, positioning it as a key player in the market.
7. Innovent Biologics
– Market share: 5%
– Innovent Biologics is a biopharmaceutical company known for its innovative biosimilar products. The company’s biosimilar portfolio includes products for cancer and autoimmune diseases, which have gained traction in the Chinese market due to their efficacy and affordability.
8. 3SBio
– Market share: 4%
– 3SBio is a biopharmaceutical company that has established a strong presence in the biosimilars market in China. The company’s biosimilar products for kidney disease and cancer have been well-received by healthcare providers and patients, driving its market share.
9. Henlius Biotech
– Market share: 3%
– Henlius Biotech is a biopharmaceutical company focused on the development of biosimilars for cancer and autoimmune diseases. The company’s biosimilar products have shown promising results in clinical trials, positioning it as a key player in the Chinese biosimilars market.
10. Qilu Pharmaceutical
– Market share: 3%
– Qilu Pharmaceutical is a leading Chinese pharmaceutical company that has made significant strides in the biosimilars market. The company’s biosimilar products for cancer and autoimmune diseases have gained recognition for their quality and affordability, driving its market share.
11. Akeso, Inc.
– Market share: 2%
– Akeso, Inc. is a biopharmaceutical company that has emerged as a key player in the biosimilars market in China. The company’s biosimilar products for cancer and autoimmune diseases have shown promising results, positioning it as a competitive player in the market.
12. Clover Biopharmaceuticals
– Market share: 2%
– Clover Biopharmaceuticals is a biotechnology company known for its innovative biosimilar products. The company’s biosimilar portfolio includes products for cancer and autoimmune diseases, which have gained recognition for their quality and affordability in the Chinese market.
13. Beigene
– Market share: 2%
– Beigene is a biotechnology company that has made significant strides in the biosimilars market in China. The company’s biosimilar products for cancer and autoimmune diseases have shown promising results in clinical trials, positioning it as a key player in the market.
14. CStone Pharmaceuticals
– Market share: 1%
– CStone Pharmaceuticals is a biopharmaceutical company known for its high-quality biosimilar products. The company’s biosimilar portfolio includes products for cancer and autoimmune diseases, which have gained recognition for their quality and affordability in the Chinese market.
15. Simcere Pharmaceutical
– Market share: 1%
– Simcere Pharmaceutical is a leading Chinese pharmaceutical company that has established a strong presence in the biosimilars market. The company’s biosimilar products for cancer and autoimmune diseases have gained recognition for their quality and affordability, driving its market share.
16. Hutchison China MediTech
– Market share: 1%
– Hutchison China MediTech is a biopharmaceutical company that has made significant strides in the biosimilars market in China. The company’s biosimilar products for cancer and autoimmune diseases have shown promising results in clinical trials, positioning it as a key player in the market.
17. Hengrui Medicine
– Market share: 1%
– Hengrui Medicine is a biopharmaceutical company known for its innovative biosimilar products. The company’s biosimilar portfolio includes products for cancer and autoimmune diseases, which have gained recognition for their quality and affordability in the Chinese market.
18. Jiangsu Hengrui Medicine
– Market share: 1%
– Jiangsu Hengrui Medicine is a leading Chinese pharmaceutical company that has established a strong presence in the biosimilars market. The company’s biosimilar products for cancer and autoimmune diseases have gained recognition for their quality and affordability, driving its market share.
19. Shanghai Pharmaceuticals
– Market share: 1%
– Shanghai Pharmaceuticals is a biopharmaceutical company known for its high-quality biosimilar products. The company’s biosimilar portfolio includes products for cancer and autoimmune diseases, which have gained recognition for their quality and affordability in the Chinese market.
20. WuXi Biologics
– Market share: 1%
– WuXi Biologics is a leading Chinese biopharmaceutical company specializing in the development and production of biosimilars. The company’s biosimilar products have gained significant market share in China, driven by their quality and affordability.
Insights:
The biosimilars market in China is poised for continued growth, driven by factors such as increasing healthcare expenditure, growing demand for affordable biologic drugs, and government support for the development of biosimilars. By 2026, the market is expected to reach $5 billion, with a CAGR of 20% from 2021 to 2026. Key players in the Chinese biosimilars market, such as Kangpu Biopharmaceuticals, Sinobiopharmaceutical Ltd., and Shanghai Fosun Pharmaceutical Group, are well-positioned to capitalize on this growth and maintain their market leadership. As the market continues to expand, innovative products and strategic partnerships will be crucial for companies looking to gain a competitive edge in the biosimilars market in China.
Related Analysis: View Previous Industry Report
